Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the high short interest stocks to buy right now.
Dyne Therapeutics Inc. (DYN)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Siren L.L.C. Raymond Debbane | 4,729,174 | $59,824,051 | -3% | 2.34% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 3,554,000 | $44,958,100 | +12% | 0.07% |
| 3. | Citadel Investment Group Ken Griffin | 3,413,435 | $43,179,952 | +262% | 0.01% |
| 4. | Armistice Capital Steven Boyd | 3,064,000 | $38,759,600 | +20% | 0.57% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 3,013,377 | $38,119,219 | +573% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.11 | 100,000 | $911,000.00 | 242,179 | 2025-07-14 | Filing | |
| $33.09 | 7,200 | $238,248.00 | 8,000 | 2024-09-04 | Filing | |
| $32.57 | 800 | $26,056.00 | 800 | 2024-09-04 | Filing | |
| $33.09 | 7,200 | $238,248.00 | 8,000 | 2024-09-04 | Filing | |
| $32.57 | 800 | $26,056.00 | 800 | 2024-09-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.72 | 2,662 | $55,156.64 | 196,877 | 2025-12-05 | Filing | |
| $20.72 | 880 | $18,233.60 | 87,510 | 2025-12-05 | Filing | |
| $20.72 | 144 | $2,983.68 | 94,729 | 2025-12-05 | Filing | |
| $13.41 | 2,640 | $35,402.40 | 199,539 | 2025-09-05 | Filing | |
| $13.41 | 144 | $1,931.04 | 94,873 | 2025-09-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,745,505 | $186,489,080 | 0.09% | |
| 2. | 9,760,414 | $123,469,238 | 0% | |
| 3. | 9,634,909 | $121,881,599 | 0% | |
| 4. | 9,130,465 | $115,500,382 | 15.35% | |
| 5. | 5,462,846 | $69,105,002 | 13.81% |
News See All
11 High Short Interest Stocks to Buy Right Now
On December 8, Bob Doll, Crossmark Global Investments CEO and CIO, joined CNBC’s ‘Squawk on the Street’ to discuss the latest market trends and his expectations for the Fed.
Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate
Dyne Therapeutics jumped by 9.47 percent on Monday to finish at $22.20 apiece as investors cheered the encouraging results from its ongoing clinical trial to test the efficacy of therapy candidate, zeleciment...
Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best upside stocks to buy now.
Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger
Dyne Therapeutics soared by 41.18 percent on Monday to close at $24.17 apiece following a comment from investment firm Jefferies that it would likewise benefit from Novartis’ $12 billion planned acquisition...
Dyne's Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One Year
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best hot stocks to invest in.
12 Best Hot Stocks to Invest In
On September 24, Ryan Detrick, Carson Group chief market strategist, joined CNBC's 'Power Lunch' to discuss why he still expects a strong end-of-year rally.
Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best stocks to buy under $20.
10 Best Stocks to Buy Under $20
On September 16, Ali Dibadj, Janus Henderson Investors CEO, joined 'Squawk Box' on CNBC to discuss the latest market trends and suggest that small and mid-cap stocks have enormous potential to deliver...
Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating
Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 14 Best Small Cap Stocks to Buy Right Now. On August 25, Raymond James increased the price target on Dyne Therapeutics, Inc.
Hedge Fund Resource Center Billionaire Hedge Funds
